Table 1.

Induction and consolidation therapy Total XIIIA and XIIIB

Window Methotrexate (1 g/m2 or 30 mg/m2 every 6 h × 6), mercaptopurine (1 g/m2), or methotrexate plus mercaptopurine, day 137 38  
Induction Pred (40 mg/m2/d), days 5–33  
 VCR (1.5 mg/m2/wk × 4), days 5, 12, 19, and 26 
 Daunorubicin (25 mg/m2), days 5 and 12 
 Asparaginase (10 000 U/m2) start, day 5; thrice weekly × 2 weeks (3 weeks in those with poor early response) 
 VP (300 mg/m2) + (AraC 300 mg/m2), days 27, 30, and 34  
 XIIIA only: randomize G-CSF vs placebo at day 35  
Consolidation HDMTX (2 g/m2) days 48 and 55 + MP (75 mg/m2/day) × 14 days 
Window Methotrexate (1 g/m2 or 30 mg/m2 every 6 h × 6), mercaptopurine (1 g/m2), or methotrexate plus mercaptopurine, day 137 38  
Induction Pred (40 mg/m2/d), days 5–33  
 VCR (1.5 mg/m2/wk × 4), days 5, 12, 19, and 26 
 Daunorubicin (25 mg/m2), days 5 and 12 
 Asparaginase (10 000 U/m2) start, day 5; thrice weekly × 2 weeks (3 weeks in those with poor early response) 
 VP (300 mg/m2) + (AraC 300 mg/m2), days 27, 30, and 34  
 XIIIA only: randomize G-CSF vs placebo at day 35  
Consolidation HDMTX (2 g/m2) days 48 and 55 + MP (75 mg/m2/day) × 14 days 

Pred indicates prednisone; VCR, vincristine; VP, etoposide; AraC, cytarabine; HDMTX, high-dose methotrexate; and MP, mercaptopurine.

View Large